SAN DIEGO, July 29, 2021 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that a class motion lawsuit has been filed on behalf of purchasers of Frequency Therapeutics, Inc. (NASDAQ: FREQ) common inventory in between November 16, 2020 and March 22, 2021, inclusive (the “Course Period”). The Frequency Therapeutics course action lawsuit rates Frequency Therapeutics and specified of its executives with violations of the Securities Exchange Act of 1934. The Frequency Therapeutics course motion lawsuit (Evans v. Frequency Therapeutics, Inc., No. 21-cv-10933) was submitted in the District of Massachusetts and is assigned to Choose William G. Younger. A similar lawsuit (Hingston v. Frequency Therapeutics, Inc., No. 21-cv-11040) is also pending in the District of Massachusetts.

If you suffered sizeable losses and would like to serve as guide plaintiff of the Frequency Therapeutics class motion lawsuit, please supply your info by clicking below. You can also call lawyer J.C. Sanchez of Robbins Geller by calling 800/449-4900 or by means of e-mail at [email protected] Guide plaintiff motions for the Frequency Therapeutics course action lawsuit need to be submitted with the courtroom no afterwards than August 2, 2021.

Case ALLEGATIONS: The Frequency Therapeutics class action lawsuit alleges that, shortly just after launching the Phase Fx-322 2a demo, Frequency Therapeutics and its Main Govt Officer, defendant David L. Lucchino, realized that the Stage 2a demo results exposed no discernable distinction concerning Forex-322 and the placebo. The Frequency Therapeutics course motion lawsuit further alleges that, while Frequency Therapeutics’ inventory value remained artificially inflated, defendant Lucchino offered more than 350,000 Frequency Therapeutics shares, pocketing more than $10.5 million.

On March 23, 2021, Frequency Therapeutics disclosed deeply disappointing interim Stage 2a effects, revealing that topics with gentle to average severe sensorineural listening to loss did not display improvements in hearing steps compared to placebo. On this information, Frequency Therapeutics’ inventory value fell by practically 78%, harming traders.

THE Guide PLAINTIFF Course of action: The Personal Securities Litigation Reform Act of 1995 permits any investor who bought Frequency Therapeutics prevalent stock all through the Class Interval to request appointment as guide plaintiff in the Frequency Therapeutics class action lawsuit. A guide plaintiff is typically the movant with the best financial fascination in the aid sought by the putative class who is also normal and satisfactory of the putative class. A lead plaintiff functions on behalf of all other course associates in directing the Frequency Therapeutics class action lawsuit. The lead plaintiff can pick a legislation company of its option to litigate the Frequency Therapeutics course motion lawsuit. An investor’s means to share in any potential long term restoration of the Frequency Therapeutics course motion lawsuit is not dependent upon serving as lead plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 legal professionals in 9 places of work nationwide, Robbins Geller Rudman & Dowd LLP is the most significant U.S. law company symbolizing investors in securities class steps. Robbins Geller lawyers have attained several of the premier shareholder recoveries in historical past, which include the most significant securities class motion restoration at any time – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Course Motion Companies Top rated 50 Report ranked Robbins Geller initially for recovering $1.6 billion for traders very last calendar year, more than double the total recovered by any other securities plaintiffs’ firm. Be sure to stop by https://www.rgrdlaw.com/organization.html for a lot more information.

Lawyer marketing.
Past success do not ensure foreseeable future outcomes.
Services might be done by lawyers in any of our workplaces.

Get hold of:
Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
[email protected]

Cision

View first information:https://www.prnewswire.com/news-releases/monday-deadline-traders-with-significant-losses-have-possibility-to-direct-the-frequency-therapeutics-inc-course-motion-lawsuit—freq-301343704.html

Resource Robbins Geller Rudman & Dowd LLP